Effective use of Silymarin as a promising P-Glycoprotein Inhibitor in the Management of Breast Cancer

Abstract

Objectives: Chemotherapy has various side effects and toxins, to overcome these problems nanoparticles are formed. Nanoparticles accumulate in tumor cells due to EPR effect. Given the role of P-gp in influencing drug’s pharmacology, methods to overcome P-gp mediated efflux have been investigated. The objectives of present research were to formulate nanoparticles containing DOX and PTX. The present research also includes the potential of flavonoids such as silymarin (SLM) to act as    P-gp inhibitors, enabling increased absorption and inhibition of excretion and modulation of multi-drug resistance. 
 Materials and Methods: Nanoparticles of PLGA and BSA were developed paclitaxel (PTX). Using 23 factorial designs total eight formulations of PTX-PLGA and PTX-BSA nanoparticles were prepared. PLGA (A,) poly vinyl alcohol (PVA) (B) and speed (C) used as independent variants in size of the particles (Y1), efficiency of entrapment (Y2) and % release of drug (Y3) taken as a dependent variable. PTX was successfully applied to the micelles by dissolving.
 Results: The median diameter of PTX-BSA and PTX-PLGA nanoparticles ranged from 104 to 1150 nm and 110 to 1023 nm respectively. The effectiveness of the entrapment and release of in vitro drugs also rely on the solubility of the drug and the polymer in the solvent. The use of software is a systematic tool for optimization, and it helps to reduce the cost of experiments.
 Conclusion: From the experiments it was concluded that the prepared formulation helped to overcome the multiple drug resistance by incorporation of P-gp inhibitor like silymarin.